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Abstract
The administration of certain monoclonal anti-Sm antibodies
(2G7, 7.13) induced most MRL/lpr mice to become anti-Sm
positive by 5 mo of age, although other anti-Sm monoclonals
(Y2, Y12) suppressed the spontaneous response. Positive
anti-Sm antibody enhancement occurred efficiently only in
MRL/lpr mice and not in other systemic lupus erythematosus
mice that have little spontaneous anti-Sm production. The en-
hancement by anti-Sm antibodies was specific for the anti-Sm
response. The mechanism of the passive antibody enhance-
ment was apparently not isotype- or idiotype-related. The fine
specificity of the anti-Sm monoclonal antibody may be essen-
tial to its enhancing or suppressing effects, since both enhanc-
ing monoclonals recognized only the D Sm polypeptide,
whereas both suppressing monoclonals saw the D and the B
polypeptides. Furthermore, analysis of serial bleeds from un-
manipulated MRL mice that developed anti-Sm positivity
showed that the D specificity almost always appeared first. We
hypothesize, therefore, that those animals in which an anti-Sm
response is initiated by D-specific B-cell clones can become
serologically positive with the aid of a positive feedback loop.
In contrast, animals in which the initial specificity is for both B
and D peptides would be prevented from developing a full
anti-Sm response. (J. Clin. Invest. 1990. 85:86-92.) mixed
leukocyte reaction * monoclonal anti-Sm antibody - passive
antibody- systemic lupus erythematosus mice
Introduction
Anti-Sm antibodies are specific markers ofsystemic lupus ery-
thematosus (SLE)' in humans and in murine models of this
disease (1, 2). These autoantibodies are directed at one or more
peptides of nuclear RNA-protein complexes, termed small
nuclear ribonucleoproteins (snRNPs [3]), and are predomi-
nantly of the IgG isotypes (4, 5). Only a minority of humans
with SLE develop this specificity; remarkably, this is also the
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case for genetically identical SLE-prone mice. We have pre-
viously investigated in detail the expression of anti-Sm anti-
bodies in the inbred MRL mouse strains in order to elucidate
this unusual pattern of autoantibody production (6). We
found that 5-mo-old MRL/Mp-lpr/lpr (MRL/lpr) mice have a
25% prevalence of anti-Sm positivity, as determined by im-
munodiffusion. Quantitative analysis with a much more sen-
sitive ELISA assay indicated that immunodiffusion-positive
sera had high titers of anti-Sm antibodies, whereas immuno-
diffusion-negative sera were indistinguishable from sera ob-
tained from normal mice. The distribution of anti-Sm posi-
tivity among a large cohort ofMRL/lpr mice ofknown lineage
showed no evidence for genetic, parental, or environmental
factors that might determine whether an individual became
anti-Sm positive. These data suggested that the initiation of
the anti-Sm response depends on stochastic factors in the on-
togeny of an individual, and that once an animal becomes
positive, its response is amplified by a positive feedback sys-
tem. Such stochastic factors must interact with genes in the
MRL background, as only this strain spontaneously produces
anti-Sm antibodies.
In the current study, we have developed a model of a feed-
back system by determining the effect of passively infused
anti-Sm antibodies in SLE mice. Our findings confirm that
some anti-Sm monoclonal antibodies can favor the further
endogenous production of this specificity (7, 8). We have de-
termined that this effect requires the appropriate genetic back-
ground, that it is antigen-specific, that it probably does not
operate through idiotypic networks or through a single isotype,
and that it probably requires recognition of particular epitopes
on the D peptide of the Sm complex. In addition, serial analy-
sis ofthe fine specificity of sera from MRL mice that spontane-
ously developed anti-Sm antibodies was consistent with a spe-
cial role of the D peptide in initiating the anti-Sm response.
Methods
Mice. MRL/Mp-lpr/lpr (MRL/lpr), MRL/Mp-+/+ (MRL/+), and
C57BL/6-lpr/lpr (B6-lpr) were obtained from our colony at the Uni-
versity of North Carolina at Chapel Hill or directly from the Jackson
Laboratory (Bar Harbor, ME). Lpr homozygous Fl hybrids were bred
by crossing MRL/lpr females with B6/lpr males (MB/lpr), or B6/lpr
females with MRL/lpr males (BM/lpr). Mice were sex-matched in each
experiment.
Antibodies. Monoclonal anti-Sm antibodies or control antibodies
were produced as ascites in (MRL/+ X BALB/c) Fl mice. They were
purified on staphylococcal protein A and stored frozen until use. The
following antibodies were used (Table I): 2G7 (9), 7.13 (the kind gift of
Dr. Sallie 0. Hoch, Agouron Institute, La Jolla, CA [10]), Y2 and Y12
(the kind gift of Drs. Ethan Lerner and Joan Steitz, Yale University,
New Haven, CT [ 1 1]), 5N (12), 6/0 (13), and 220 (the kind gift of Dr.
Kim Hasenkruz, McLaughlin Institute, Great Falls, MT). All MAbs
except 220 were originally from MRL/lpr mice.
Passive antibody protocol. Mice were prebled at the age of 4-6 wk
86 Eisenberg et al.
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/90/01/0086/07 $2.00
Volume 85, January 1990, 86-92
Table I. Monoclonal Antibodies Utilized
Name Isotype Specificity Source Reference
2G7 IgG2a, K Sm (D) Pisetsky 9
Y2 IgG2a, K Sm (B, D) Steitz 11
Y12 IgG3, K Sm (B, D) Steitz 11
7.13 IgG3, K Sm (D) Hoch 10
220 IgG3, K H-2f Hasenkruz
5N IgG2a, K Chromatin (DNA) Pisetsky 12
6/0 IgG2a, K DNA Pisetsky 13
and then injected intraperitoneally once a week with 300 gg of purified
monoclonal antibodies in 0.5 ml of phosphate-buffered saline (PBS).
They were bled monthly immediately before the weekly injection. Sera
were tested by immunodiffusion as they were accumulated. When a
mouse was determined to be anti-Sm positive, its injections were
discontinued.
Assays. Anti-Sm antibodies were detected by immunodiffusion
against rabbit thymus extract, as described (2). In some experiments,
sera were also tested by ELISA, using affinity-purified rabbit Sm (14).
The IgG subclass of anti-Sm antibodies was similarly determined by
ELISA, as previously reported (5). Anti-chromatin antibodies were
also measured by ELISA, using chicken erythrocyte chromatin (15).
Anti-idiotypic antibodies to the 2G7 monoclonal were raised by
immunizing rabbits with purified 2G7. The resultant antiserum was
exhaustively absorbed on a solid phase column made with the 6/0
protein, an MRL anti-DNA monoclonal with the same isotype
(IgG2a). Anti-idiotypic antibodies were then affinity-purified on a
2G7 column, and these antibodies were conjugated with biotin. They
were further absorbed with solid-phase 6/0 immediately before use.
2G7 idiotype-positive anti-Sm antibodies were detected by ELISA as
follows: Affinity-purified Sm antigen at a predetermined optimal con-
centration was coated on microtiter plates in borate-buffered saline for
5 h at 4VC. After blocking nonspecific binding with BSA and Tween,
samples (either monoclonal antibody or sera) were added at varying
dilutions. After overnight incubation, the absorbed biotinylated anti-
idiotype antibody was added at a 1:1000 dilution. The assay was then
developed with avidin-alkaline phosphatase and substrate. This assay
could detect as little as 1 ng of the 2G7 antibody. Its cross-reactivity
with Y12, 7.13, or Y2 monoclonals was <0.1%. The results with
individual sera were compared with a standard curve made with puri-
fied 2G7 protein and calculated as micrograms per milliliter of 2G7
idiotype. To determine total anti-Sm, each serum was simultaneously
tested in a K light chain-specific anti-Sm assay and compared with a
curve made with the Y2 protein. The Y2 standard was used because
dilution of this protein gave an OD curve that was superimposable on
that produced by diluting anti-Sm-positive sera.
Sera from passive antibody-treated MRL/lpr mice or from un-
manipulated MRL mice were subjected to Western blotting as follows:
Affinity-purified Sm was prepared for electrophoresis by boiling I vol
of antigen (2 mg/ml) with 1 vol of sample buffer containing 0.0625 M
Tris, 2% wt/vol sodium dodecyl sulfate (SDS), 5% 2-mercaptoethanol
vol/vol, and 10% vol/vol glycerol. The diluted sample was electro-
phoresed on a 3.5% polyacrylamide stacking gel and 12.5% polyacryl-
amide resolving slab gel in an electrode buffer (0.025 M Tris hydrox-
ide, 0.192 M glycine, and 1% wt/vol SDS). Electrophoresis was per-
formed at 20°C for 2.5 h at 40 mA per gel with constant current using a
modification of the procedure described by Laemmli (16). The sepa-
rated polypeptides were transferred to nitrocellulose by electroblotting
in transfer buffer (I150 mM glycine, 25 mM Tris hydroxide, 20% meth-
anol, pH 8.3) at 100% voltage for 1.5 h at 10°C. The nitrocellulose
paper was then blocked with a solution ofPBS-5% BSA for 2 h. Strips 6
mm wide were cut from the nitrocellulose paper and incubated with
sera diluted in blotting buffer (PBS, 0.85% Tween 80, 1% BSA). The
sera were used at dilutions at which they gave comparable ODs by
ELISA. After incubation with the sera, the strips were incubated with
peroxidase-labeled goat anti-mouse IgG or rabbit anti-human IgG
(Cappel-Worthington Biochemicals, Malvern, PA) diluted in blotting
buffer to 1:500 and 1:250, respectively. The bound antibodies were
visualized by adding the horseradish peroxidase color development
reagent (Bio-Rad Laboratories, Richmond, CA), as suggested by the
supplier.
Results
Genetics ofanti-Sm induction. In preliminary experiments, we
demonstrated the induction of anti-Sm antibodies in MRL/+
mice by injections of the 2G7 monoclonal anti-Sm. Adminis-
tration of 0.3 and 0.03 mg per mouse per week of the 2G7
monoclonal antibody caused most MRL/+ mice to become
anti-Sm positive, whereas weekly doses of 3 and 0.003 mg per
mouse per week were ineffective (data not shown). The 0.3-mg
dose was chosen for all subsequent experiments.
The detection of spontaneous anti-Sm antibody produc-
tion in the presence of the passively administered antibody did
not pose a problem for several reasons. 2G7 antibody, by itself,
is not precipitating, and thus was not detected in the double-
immunodiffusion screening. In addition, the amount of pas-
sive antibody that remained 1 wk after injection was, in most
cases, substantially less than the amount detected by ELISA in
those mice that had begun endogenous production. Passive
antibody administration was discontinued in those animals
that had become immunodiffusion-positive, so that subse-
quent bleeds would have vanishingly small amounts of per-
sisting passive antibody. Furthermore, as demonstrated below,
the isotype and the idiotype of the endogenously produced
anti-Sm antibody could not be explained by the passively ad-
ministered material.
Passively administered anti-Sm antibody increased the
likelihood ofendogenous anti-Sm production preferentially in
mice with the genetic capacity to produce this autoantibody
spontaneously (6). As shown in Fig. 1, MRL/lpr treated with
2G7 developed the early appearance of anti-Sm antibodies
(30% of mice positive at 12 wk of age), and by 5 mo of age (16
wk after injection) > 80% were positive. MRL/lpr mice in-
jected with the 5N control antibody developed the expected
25-30% prevalence of anti-Sm positivity at 5 mo of age. In
contrast, B6/lpr mice, which do not spontaneously produce
anti-Sm antibodies, were much less affected by the 2G7 injec-
tions, as only a single animal became positive at 6 mo of age.
MB/lpr mice, which normally have about a 4% incidence of
anti-Sm antibodies at 5 mo of age (unpublished data), tended
to be intermediate in their susceptibility to anti-Sm induction
by 2G7. Only one BM/lpr mouse has responded, although
fewer such mice have been investigated.
Effects of different monoclonal anti-Sm antibodies. Four
different anti-Sm monoclonal antibodies were used in the
passive-antibody experiments: 2G7 and Y2 (both IgG2a, K),
and 7.13 and Y 12 (both IgG3, K). Isotype-matched control
proteins of other specificities were also administered. As
shown in Fig. 2, which illustrates pooled data from three ex-
periments with similar results, 2G7 was the most potent in
inducing anti-Sm antibodies, but 7.13 also had a significant
effect. The control antibodies SN and 220 induced no more
anti-Sm than would be expected to occur spontaneously,
while the Y2 and Y12 antibodies suppressed endogenous
anti-Sm production. The weekly administration of Y2 to-

















N Figure 2. Effects of different MAb on induction of anti-Sm in MRL/
/Ipr 28 lpr mice. MRL/lpr mice 4-6 wk old were treated with weekly injec-
pr 21 tions of 0.3 mg per mouse of anti-Sm (solid lines) or control mono-
Pr 6 clonals (dashed lines). Anti-Sm positivity was determined by immu-
nodiffusion. Results represent pooled data from three experiments
with similar results. N indicates the total number of mice initiated
into each group. The effects of 2G7 in inducing anti-Sm were greater
than all other monoclonals (P < 0.001) for 8-16 wk, except vs. 7.13
at 12 wk (P = 0.05) and at 16 wk (not significant). The 7.13-treated
group had a significantly higher prevalence of anti-Sm than the Y 12
group at 12 and 16 wk (P < 0.01) and was significantly greater than
_ the pooled results ofthe control proteins (5N + 220) at 12 and 16
4 8 12 16 20 wk (P 0.05). The Y2 had significantly less anti-Sm than the
Weeks 5N group (P < 0.05 at 8 and 12 wk), while the difference between
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Figure 1. Genetics of anti-Sm induction by passive antibody. Ani-
mals 4-6 wk old of the indicated strains were injected intraperitone-
ally with 0.3 mg/wk of (upper panel) anti-Sm (2G7) or (lower panel)
control (5N). Mice were bled monthly and typed for endogenous
anti-Sm production by double immunodiffusion. Results shown
have been pooled from three experiments with similar outcomes.
The N listed indicates the total number of mice entered into the ex-
periments. The prevalence of anti-Sm positivity in the 2G7-treated
MRL/lpr mice was significantly greater by x2 analysis than that in-
duced by 2G7 in all other groups (P < 0.001 at 12, 16, and 20 wk)
and different from that seen in SN-treated MRL/lpr mice (P < 0.01
at 8-20 wk). The modest induction of anti-Sm in MB/lpr mice by
2G7 did not reach statistical significance in comparison with the B6/
lpr and BM/lpr groups.
gether with 2G7, each at a dose of0.3 mg, gave an incidence of
anti-Sm similar to that produced by Y2 alone.
The comparisons shown in Fig. 2 were confirmed by
ELISA (not shown). Interestingly, the amounts of anti-Sm
antibody in immunodiffusion-positive sera did not depend on
the mode of induction (Table II), except for somewhat lower
values in 7.13-treated animals (P < 0.05).
The differing effects of the various monoclonals tested
suggested a possible role for isotype or idiotype in the induc-
tion of anti-Sm. However, the fact that monoclonals of two
isotypes (IgG2a, IgG3) could either induce anti-Sm (2G7,
7.13) or suppress anti-Sm (Y2, Y12) argued against a simple
isotype-related mechanism. In addition, the relative IgG sub-
class distribution of anti-Sm antibodies in mice receiving 2G7
or 7.13, and in controls was remarkably consistent (Fig. 3).
This would not be expected if, for example, the mechanism of
2G7 anti-Sm induction involved isotype-specific T cell help or
suppression ( 17).
The possibility that idiotype network interactions might
play a role in passive antibody induction of anti-Sm was in-
vestigated by measuring the level of 2G7 idiotype in treated
eI1C I hgroup mLeLcntrul proteCins uau nut r[cintIListal sig-
nificance.
and untreated MRL/lpr mice. Table III shows that the pre-
bleed sera had very little anti-Sm antibody or 2G7 idiotype. At
4 wk after the initiation of injections, passively carried-over
anti-Sm was detectable. In those animals treated with 2G7, a
mean of 19 Ag/ml of anti-Sm was present, and of this, 7.9
Asg/ml was 2G7 idiotype positive. The other groups had smaller
amounts of anti-Sm activity, with essentially no 2G7 idiotype
activity. Mice that had initiated their own endogenous produc-
tion of anti-Sm and had gone for at least a month without
passive anti-Sm had much higher levels of anti-Sm than was
seen early in the course of the experiment. However, the
amount of 2G7 idiotype-bearing anti-Sm antibodies of these
mice was still very low, even in the group that had been treated
with 2G7 (1 jtg/ml on the average).
Specificity ofanti-Sm passive enhancement. The enhanced
endogenous anti-Sm antibody production resulted from the
injection of certain anti-Sm antibodies, but not from the in-
jection of antibodies of other specificities (see Fig. 2). Con-
Table I. Anti-Sm Levels by ELISA in Anti-Sm
Immunodiffusion-positive Mice*
Treatment n Mean OD405 (±SD)
2G7 13 1.558 (±0.602)
7.13 8 1.015 (±0.396)
5N, 220 9 1.803 (±0.743)
Y2, Y12 3 1.934 (±0.896)
* Immunodiffusion anti-Sm-positive 5-mo bleed sera were tesed at a
dilution of 1O-4.





































Figure 3. IgG subclass distribution of anti-Sm antibodies in MRL/
lpr mice. Anti-Sm-positive sera from MRL/lpr mice in which mono-
clonal antibody treatment had ceased at least 1 mo previously were
tested in an isotype-specific anti-Sm ELISA. Mice had been treated
with 2G7 (open bars), 7.13 (solid bars), or, as controls, 5N, 220, or
PBS (striped bars). The percent of each isotype as compared to the
total OD for all four IgG subclasses was determined. There were no
differences among the three groups in their subclass distribution.
Error bars represent standard deviations.
versely, the enhancement ofanti-Sm autoantibody expression
induced by these anti-Sm antibodies did not affect the titers of
anti-chromatin antibodies (data not shown). In addition, the
5N monoclonal antibody, which recognizes chromatin, did
not enhance endogenous anti-chromatin production over that
seen in PBS-treated mice. The course of autoimmune disease,
as determined by survival, was modestly accelerated in 2G7-
treated mice (Fig. 4).
Specificity of anti-Sm antibodies. The specificity of anti-
Sm antibodies was determined by Western blotting. Fig. 5
shows the blots obtained with the monoclonal antibodies uti-
lized. As has been reported, the 2G7 and 7.13 antibodies recog-
nized the D peptide, while the Y2 and Y12 antibodies saw
Table III. 2G7 Idiotype in Anti-Sm-positive Passive
Antibody-treated Mice
Treatment
2G7 Other anti-Sm* Controlt
Bleed (n= 15) (n= 12) (n= 12)
Wg/mi by ELISA
Prebleed
Anti-Sm 0.8 (±0.8) 0.8 (±0.6) 0.7 (±0.8)
Idiotype 0 (±0) 0.02 (±0.07) 0 (±0)
4 wk
Anti-Sm 19 (±13) 6 (±6) 7 (±17)
Idiotype 7.9 (±8.2) 0 (±0) 0.02 (±0.05)
Immunodiffusion positive1
Anti-Sm 553 (±673) 274 (±206) 570 (±641)
Idiotype 1.0 (±1.8) 0.7 (±1.0) 0.4 (+0.5)
* Selected mice that had been treated with Y2, Y12, or 7.13 and had become
anti-Sm positive.
t Selected mice that had been treated with 5N, 220, or PBS and had become
anti-Sm positive.




Figure 4. Survival of passive antibody-treated mice. Mortality data
were pooled from five separate, similar experiments. Enhanced mor-
tality in the 2G7-treated animals was significant at the ages of 21-24
wk (P < 0.01).
both the B and D peptides (10, 18, 19). Fig. 6 shows represen-
tative blots from passive antibody-induced sera. Even though
the inducing antibody (2G7) only saw the D peptide, the re-
sultant positive sera saw at least one additional epitope, pres-
ent on the B and B' peptides, and by Western blot were indis-
tinguishable from anti-Sm-positive sera from unmanipulated
mice.
These results were compared with Western blots of serial
bleeds of MRL/lpr and MRL/+ mice that spontaneously de-
veloped anti-Sm reactivity. Seven MRL/lpr and six MRL/+
were studied. All the MRL/+ recognized the D band at the
time of the initial anti-Sm response. Five of the sera reacted








Figure 5. Western blot of anti-Sm antibodies used in passive anti-
body experiments. Purified Sm/RNP antigen was run on polyacryl-
amide gels, transferred to nitrocellulose, and probed with the follow-
ing reagents: lane A, UPC 10, an IgG2a myeloma protein; lane B,
2G7; lane C, Y2; lane D, Y12; lane E, 7.13; lane F, BALB/c serum;
lane G, anti-Sm-positive MRL/lpr serum; lane H, CDC anti-Sm
standard; lane I, CDC anti-RNP standard. The staining by 2G7 of a
high-molecular-weight band with the same mobility as that seen by
the anti-RNP serum was not consistent.
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Figure 6. Immunoblot of passive antibody-induced anti-Sm autoan-
tibodies. Sera from MRL/lpr mice making endogenous anti-Sm in
response to passive antibody induction with 2G7 were diluted to
equivalent potency on the basis of anti-Sm ELISA assays and tested
by Western blot on a purified rabbit Sm antigen: (A) BALB/c serum;
(B) UPCIO; (C-M) various passive antibody-induced sera; (N)
human SLE standard. The positions of the B and the D peptides are
marked.
only with the D band, while one serum also reacted with the B
band and the 70-kD RNP band. Six of the seven MRL/lpr
reacted only with the D band initially, and five of these six
bound additional bands in later bleeds, mainly the B and B'.
One serum did not show any positivity by blot. Fig. 7 shows
anti-Sm Western blots of serial sera from one of these MRL/
lpr mice which spontaneously acquired anti-Sm.
Discussion
We have demonstrated that the passive administration of cer-
tain monoclonal anti-Sm antibodies induced endogenous pro-
duction of anti-Sm in genetically susceptible mice. This in-
duction was specific for anti-Sm, as anti-Sm-injected animals
had no enhancement of production of anti-chromatin. Mice
injected with anti-chromatin monoclonal antibody or with
other monoclonals did not have enhanced anti-Sm produc-
tion. The anti-chromatin monoclonal antibody utilized, 5N,
which recognizes the DNA moiety of chromatin, did not en-
hance anti-chromatin production. However, we cannot con-
clude that the chromatin autoantibody system is not suscepti-
ble to the same kind of regulation until a much larger number
of antibodies is tested, particularly because half ofthe anti-Sm
antibodies used did not induce endogenous anti-Sm produc-
tion. A similar observation of passive antibody induction of
autoantibody was reported in humans for the Rh determinants
(20). The possibility of such passive antibody regulation in
other autoantibody responses remains to be investigated.
The current work suggests some aspects of the mechanism
ofthis antibody enhancement in the anti-Sm antibody system.
First, idiotypic networks do not appear to be involved. There
was no enhancement ofproduction ofthe 2G7 idiotype in 2G7
B
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Figure 7. Immunoblots on sequential sera from an anti-Sm-positive
MRL/lpr mouse. Serial sera from an individual MLR/lpr mouse
were tested at dilutions "normalized" by ELISAs on Western blots
where a purified rabbit Sm was utilized as antigen. (A) BALB/c
serum; (B-K) serial bleeds on the individual MRL/lpr mouse. Bleeds
were taken at 9, 10, 12, 13, 15, 18, 21, 24, 28, and 32 wk of age, re-
spectively.
passive antibody-induced mice. It is possible, however, that the
rabbit anti-2G7 anti-idiotypic reagent reacted with an idio-
tope of the 2G7 antibody that was not relevant to in vivo
idiotype regulation. Thus, in an MRL/lpr mouse there could
be enhancement by 2G7 of idiotopes expressed on the 2G7
molecule different from the idiotopes recognized by our rabbit
anti-idiotype reagent. We feel that this is unlikely, but it can
be ruled out only by study of the VH and VK genes utilized.
Secondly, it is unlikely that there is a specific role for isotype.
Other investigators have published that the IgG2a isotype is
capable of enhancing an immune response to exogenous anti-
gen when given with the immunogen, but that other isotypes
are immunosuppressive (21, 22). In the current work, how-
ever, the anti-Sm monoclonal antibodies that were capable of
positive enhancement were of the IgG2a and IgG3 isotypes,
whereas two anti-Sm monoclonals of the same isotypes ap-
peared to be suppressive. Thirdly, the peptide specificities of
the induced antibodies, as determined by Western blotting
(Fig. 6), suggest that the Sm antigenic particle is involved in the
mechanism of passive antibody enhancement. A role for Sm
antigen would explain the induction ofB/B' specific antibodies
by a mAb that sees only the D peptide. In this regard, the
relationship of the monoclonal antibody specificity to its en-
hancing capability is particularly striking. Those monoclonals
that recognized only the D peptide were enhancing, whereas
those monoclonals that recognized both the B and the D pep-
tides, presumably through cross-reactive epitopes, were sup-
pressive. These results suggest that the specificity ofthe mono-
clonal antibody determines its ability to enhance. Although
further anti-Sm monoclonals and additional doses need to be
tested to confirm this interpretation, this analysis parallels the
findings of Haughton and Makela (23), who showed that anti-
bodies that recognized a limited number of determinants on
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an antigenic particle could enhance an immune response,
whereas antibodies that recognized a larger set ofdeterminants
were suppressive. In addition, the two enhancing anti-Sm
monoclonals published by Maini and coworkers were D spe-
cific (7, 8).
The special role of D-peptide recognition suggested by the
monoclonal antibody-enhancement experiments parallels re-
sults in sequential analyses by Western blotting of sera from
MRL mice that spontaneously developed anti-Sm antibodies.
In every case, the initial positive serum recognized the D pep-
tide, and in all of these sera except one only the D peptide was
seen. Similar results have also been reported in a single SLE
patient who by chance had serial bleeds through the time she
became anti-Sm positive (24). Although the immunoblot
technique only detects a subset of the antibodies reacting with
a particular antigen, these results suggest that the spontaneous
anti-Sm response begins with recognition of the D peptide.
The initial anti-D response could then engender an antibody-
mediated enhancement mechanism such as we have demon-
strated.
These current results, along with our previous findings,
allow us to formulate a more detailed hypothesis regarding the
mechanism of anti-Sm production in SLE mice. We have
previously shown that spontaneous anti-Sm occurs only in
certain SLE mouse strains. Efficient induction of this specific-
ity by passive antibody requires these same strains. This sug-
gests that the genetic background determines certain common
aspects of immunoregulation of the spontaneous and passive-
antibody-induced anti-Sm responses. Even in mice with this
genotype (MRL), the frequency of precursor B cells for anti-
Sm production is very low (25). However, as our Sm-antigen
immunization experiments have shown, these B cells must
arise periodically, and under the appropriate conditions will go
on to make an anti-Sm response (26, 27). We hypothesize that
a spontaneous anti-Sm response requires the initial stimula-
tion of B cells specific only for the D peptide. If anti-Sm
antibodies of this unique specificity are thus expressed, a posi-
tive feedback loop is initiated, and the anti-Sm response is
amplified until it becomes serologically detectable. If, on the
other hand, the initial antibodies produced in response to the
Sm particle bind both the B and the D peptides, then a nega-
tive feedback loop intervenes and prevents amplification ofthe
response. As the combined effect of equivalent amounts of the
enhancing antibody and the suppressing antibody appears to
be suppressive, any response which initially included an anti-
Sm antibody of the Y2 type (anti-B, D) would fail to be am-
plified.
This schema fits with the role we postulate for stochastic
events in lymphocyte ontogeny that determine the anti-Sm
seropositivity of an MRL SLE mouse (6). According to this
admittedly oversimplified speculation, the chance of an indi-
vidual MRL/lpr animal developing an initial D peptide-spe-
cific response before the age of 5 months is - 25%. That ani-
mal would become anti-Sm seropositive. On the other hand,
the probability is 75% that an individual animal will initially
express B/D-specific clones, such that the response would be
turned off. These specificities could be determined by the ran-
dom selection and somatic mutation ofimmunoglobulin vari-
able region genes. The level of influence of the MRL genetic
factors presumably mainly occurs after this selection of the
B-cell anti-Sm specificity and functions through as yet not
understood immunoregulatory mechanisms.
Our current findings are paralleled by work from Maini
and co-workers (7, 8). They have published similar results with
enhancement of the anti-Sm response in MRL/lpr mice.
However, they also claimed that the anti-Sm-treated animals
lived longer than controls; we do not confirm this finding with
a larger number of animals, and in fact we find a modestly
decreased survival in anti-Sm-treated mice. These apparently
conflicting results may well be due to the different monoclonal
antibodies used in the two studies.
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